Skip to main content

Day: July 25, 2025

Advantage Solutions Announces Date for its Second Quarter 2025 Financial Results and Conference Call

ST. LOUIS, July 25, 2025 (GLOBE NEWSWIRE) — Advantage Solutions Inc. (NASDAQ GS: ADV) announced today that it will release financial results for the second quarter at 7 a.m. EDT on Aug. 7, 2025, followed by a conference call at 8:30 a.m. EDT on the same day. The conference call can be accessed live by dialing 1-800-715-9871 for U.S. callers or 1-646-307-1963 for international callers. The conference ID is 5720569. Approximately three hours after the call, a replay will be available by dialing 1-800-770-2030 for U.S. callers or 1-609-800-9909 for international callers. The playback ID is 5720569#. The replay recording will be available until Aug. 14, 2025. Interested investors and other parties may also listen to a simultaneous conference call webcast by logging onto the Investor Relations section of the Advantage Solutions website...

Continue reading

Stack Capital Group Inc. Announces Upsize to Its Previously Announced Best Efforts Private Placement Now Combined With the Non-Brokered Private Placement for Gross Proceeds of Up to $35,000,000

NOT FOR DISTRIBUTION TO THE UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (the “Company”) (TSX:STCK & TSX:STCK.WT.A) is pleased to announce that, as a result of strong investor demand, the Company has doubled the size of its previously announced “best efforts” private placement to up to 1,454,545 units of the Company (the “Units”) and up to $20,000,000 in gross proceeds (the “LIFE Offering”). After giving effect to the upsize of the LIFE Offering, the Company now expects to raise up to $35,000,000 in total gross proceeds under the combined LIFE Offering and Concurrent Private Placement (as defined herein). Each Unit will be issued at a price of $13.75 per Unit (the “Offering Price”)...

Continue reading

Skyward Specialty Announces Change for Second Quarter Earnings Call to Thursday, July 31 at 12 PM EDT

HOUSTON, July 25, 2025 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc.™ (NASDAQ: SKWD) (“Skyward Specialty” or “the Company”) today announced a change of its previously announced second quarter earnings call. The conference call and webcast will now be held on Thursday, July 31 at 12:00 p.m. EDT. Skyward Specialty will issue its second quarter 2025 earnings results after the market closes on Wednesday, July 30. The earnings results will be available on the Company website at investors.skywardinsurance.com/ under Quarterly Results. Investors may access the live audio webcast via the link on the Company’s investor site at investors.skywardinsurance.com/ under Events & Presentations. Additionally, investors can access the earnings call via conference call by registering via the conference...

Continue reading

ST. JAMES GOLD CORP. (TSX-V: LORD) ANNOUNCES REINSTATMENT OF TRADING, DEBT RESOLUTION, AND EXPIRED INVESTOR RELATIONS CONTRACT

Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — St. James Gold Corp. (the “Company” or “St. James”) (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) announced today that its common shares will be reinstated for trading on the TSX Venture Exchange (the “Exchange”) on or about July 29, 2025 as the TSX Venture Exchange has completed its review. The Company’s financial statements for the period ended March 31, 2025 reflected a working capital deficiency $1,905,769. In order to resolve the deficiency and comply with the Exchange listing requirements, the Company has taken the following steps:The Company has entered into agreements with its largest short-term creditors to issue unsecured notes with a maturity 18 month after issuance to satisfy their indebtedness. A total of $1,580,052.49 of short-term debt is expected to be resolved...

Continue reading

Federal Home Loan Bank of Des Moines Announces Second Quarter 2025 Financial Results, Declares Dividend

DES MOINES, Iowa, July 25, 2025 (GLOBE NEWSWIRE) — Second Quarter 2025 HighlightsNet income of $194 million Affordable Housing Program (AHP) assessments of $21 million Voluntary community and housing contributions of $43 million Advances totaled $114.8 billion Mortgage loans held for portfolio, net totaled $13.2 billion Letters of credit totaled $17.7 billion Retained earnings totaled $3.6 billionDividend The Board of Directors approved a second quarter 2025 dividend to be paid at an annualized rate of 9.75% on average activity-based stock and 6.00% on average membership stock, unchanged from the prior quarter. The Federal Home Loan Bank of Des Moines (the Bank) expects to make dividend payments totaling $145 million on August 12, 2025. Liquidity Mission The Bank provides liquidity to its members to support the housing, business,...

Continue reading

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...

Continue reading

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) —  Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...

Continue reading

LOBO EV Technologies Ltd. Issues Statement Regarding Recent Market Activity

WUXI, China, July 25, 2025 (GLOBE NEWSWIRE) — LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), a developer and manufacturer in electric mobility and intelligent systems, today issued a statement regarding recent trading activity in its common stock. The Company has observed an increase in trading volume and a corresponding decline in its share price over the past several days. While LOBO does not generally comment on market activity or fluctuations in its stock price, the Company confirms that there have been no material changes to its business operations or strategic direction that would warrant such activity. The Company continues to operate in the ordinary course of business. Current initiatives, including product development and strategic engagements, are ongoing, and management is not aware of any undisclosed...

Continue reading

Lassonde Industries Inc. Will Hold a Conference Call to Discuss Its Second Quarter 2025 Financial Results

ROUGEMONT, Quebec, July 25, 2025 (GLOBE NEWSWIRE) — Lassonde Industries Inc. (TSX: LAS.A) (“Lassonde” or the “Corporation”) is pleased to announce that it will host a conference call to discuss its financial results for the second quarter of 2025 on Friday, August 8, 2025. Mr.  Vince Timpano, Chief Executive Officer, and Mr. Eric Gemme, Chief Financial Officer, will host the call.OPEN TO:  Investors, analysts, and all interested parties   DATE: Friday, August 8, 2025   TIME: 8:30 a.m. ET   CALL: 647-846-8280 (for overseas participants)1-833-752-3549 (for other North American participants)   A live audio broadcast of the conference call will be available on the Corporation’s website, on the Investors page or here: https://www.gowebcasting.com/14099. The replay of the webcast will...

Continue reading

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) — Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment vehicle. This initiative marks a bold step toward positioning the Company at the forefront of capital innovation, as it evaluates options to diversify its long-term treasury strategy. The prospective subsidiary—which has not yet been formed and remains under active consideration—would operate independently...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.